We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.14% | 34.95 | 34.85 | 35.00 | 35.75 | 34.45 | 35.75 | 330,994 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 205.88 | 189.05M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/11/2017 17:55 | Finally on the move? Just checked my records and I bought my first 10K's worth 8th Nov 2010 at 38.5p. Hardly a stellar rise, but perhaps the next 5 years will be interesting. | 2vdm | |
03/11/2017 17:32 | Nice tick up today, hopefully it can hold above 60 | rathean | |
31/10/2017 14:39 | Some strong momentum is starting to build | reynoldsg | |
31/10/2017 11:37 | I see it as a 5 to 10 year play, but expect it to be swallowed up long before then. | dozey3 | |
31/10/2017 11:20 | Tickling 60 again, damn teaser... | rathean | |
27/10/2017 13:39 | This clearly has buying support. Very stable share price in the absence of news. A break of 60p sets a target of 80p - 400M Mcap. | petethehippy | |
27/10/2017 11:58 | I bought also as a steady as it goes dependable growth share to balance out the more risky plays. Think you need some of those. Warren Buffet has this mindset; steady as she goes and compound your investments. Over time you should do well with this strategy, but then some want quick profits and go for more risky things. | armunro | |
19/9/2017 11:45 | I have held APH for a long time, first (after a company visit)with the Loan Notes and then, on conversion, the Ordinaries. I regard it as steady share which doesn't need much attention. I think that the share price hasn't sparkled because of several factors, • There isn't a story which can excite commentators or investors. They seem to buy things here and there when cash flow allows. Admittedly they did use shares for the Sinclair deal but all this did was reduce the price. • By comparison, I also hold shares in two similar companies, Clinigen and Venture Life. CLIN is acquisitive but has a clear story to tell and a price to match. VLG is a newcomer on a similar path and does trade with APH in a small way. • APH's record so far has not excited and the problem with keeping on spending hard earned cash on acquisitions is that the intangibles dominate the balance sheet. Shareholders' Equity is shown as £187m (market cap £250m) but this includes £263m of intangibles. As far as I can establish, if a product line doesn't perform, they don't write off the associated Goodwill, they just assume that if profits are going up there is no need for an impairment charge. What happens if a major product goes off the boil? • I have argued that the company, being low growth, should be more investor friendly and pay a higher dividend that they could well afford. This would help the share price but John Dawson doesn't want to play it that way. • What is ignored by investors (because it is obscured by the constant outflow on acquisitions) is the fantastic cash flow. Mind you, even if they stopped acquiring, it would still take many years to recover the intangibles. Why do I continue to hold? Inertia partly. I did sell a good chunk at 59.5p when the opportunity arose a couple of years ago and I think patience will see us back over that level - 'When?' I hear you ask. | 123prezzie | |
13/9/2017 15:35 | https://uk.finance.y | gamwah | |
13/9/2017 12:17 | 2vdm: perhaps the word you are looking for is "cart-horse" Been on my watch list for ages but cannot see significant capital appreciation but probably better overall yield than cash in a savings account. | pugugly | |
13/9/2017 12:12 | Interims show good solid progress,increased profits, M@shield doing well, loans reducing and a healthy cash position. The only surprise for me is that there seems to be little interest shown. I'm just going to keep adding as I think this is well under the radar. It's not a racehorse, but jogs along and in the right direction. Well done to the mngt. and I look fwd to news during H2. | 2vdm | |
30/8/2017 18:04 | Interims due for 6 months to 30th June to be announced on 13th September, so unless N Korea causes chaos, we should see increased interest here. | 2vdm | |
31/7/2017 08:47 | The timing of such news is always going to be difficult, however 9 mins before close (16.21hrs) on last day of the week certainly 'leaves a bad taste'. APH's BoD will need to consider more transparency on the timetable leading up to this announcement to retain credibility. Regulatory Approval for any of their products (or disapproval) is a matter of some significance to share price value. Particularly when not long ago APH was anticipating £250mln 'potential sales of Diclectin across UK/European market with a differentiated product addressing an unmet need.' For details, see: | mazarin | |
28/7/2017 23:23 | Diclectin works-but is controversial-not allowed in many countries but widely used in Canada I think for years which surprises me that the MHRA even agreed to accept it for review, in which case i would have expected them to pass it as much of the clinical data is in the public domain so it may be a technical issue, ? marketing-esp as aimed at pregnant women so particularly sensitive area. Could be double edged sword for APH if accepted-big demand-no real alternatives save remedies like vitamins etc but wonder if NICE had input and got cold feet-everyone remembers Thalidomide- and diclectin has been the subject of numerous lawsuits in past I believe so maybe not a major loss for APH. Presume more info will come out from APH-this evenings was clearly rushed before market close. Whoever bought shares at 55p during week-had to be II who wont be happy if APH had inkling of news or there was a leak from MHRA which went to certain big holders (in which case huge mgmt repercussions) but I doubt if anyone knew. Aimo-dyor | cumnor | |
28/7/2017 23:03 | Cisk, I also thought it was a marketing issue when I read the rns however after looking into it I think it may be that there is no proof that it actually works...if that is the case then it's serious. hxxp://www.ctvnews.c | blindsquirrel | |
28/7/2017 22:46 | Reading the rns it says the marketing submission has been rejected, presumably not the product? So aph need to submit revised marketing text for the product? Apologies if it's more complex than this. I'm sure bank of can and wray were unaware of this - wray still owns a fair chunk. Would be interesting to find out exactly when the company got this news though... | cisk | |
28/7/2017 17:14 | How we know why Nigel Wray; sold a large chuck of his holding. Disappointed with this company's actions. | williamgtheobald | |
28/7/2017 17:12 | Me to, I sold around 50p a while back and thought I'd missed the boat. Oh how things change, if it does go back to the 40's I could be interested again. | buying | |
28/7/2017 17:01 | Yeah me too sold mine, bank of canada sold recently! | rolo7 | |
28/7/2017 16:59 | I thought better of this company than to issue an RNS at 4.20. I wonder if it will drift into the mid 40's | buying | |
28/7/2017 16:33 | And are you telling me those big sellers just got "lucky" this week. | davr0s | |
28/7/2017 16:26 | Don't you just love a Friday 4.21 RNS to spoil the weekend | davr0s |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions